ARA 290
ARA 290 is a peptide, indexed here under Tissue repair peptides.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Tissue repair peptides |
| CAS registry number | 1208243-50-8[1] |
| PubChem CID | 91810664[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C51H84N16O21[1] |
| Molecular weight | 1257.3 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
ARA 290, generic name cibinetide, is described in a 2014 Molecular Pain paper as a peptide derived from the tertiary structure of erythropoietin and in a 2016 Transplantation paper as a nonhematopoietic erythropoietin analogue. A 2020 Toxicology in Vitro paper reports attenuation of doxorubicin-induced genotoxicity in its model, and a 2022 Brain, Behavior and Immunity paper reports early monocyte modulation in a model of Alzheimer-like pathology.
The clinical records are in sarcoidosis-associated small fibre neuropathy: a 2012 Molecular Medicine randomised double-blind study, a 2013 paper in the same journal on symptoms and corneal nerve fibre density, a 2014 Expert Opinion on Investigational Drugs review, a 2015 Molecular Medicine paper reporting metabolic control and neuropathic symptom endpoints, and a 2017 Investigative Ophthalmology and Visual Science paper on corneal nerve fibre abundance. Other preclinical records include a 2017 Scientific Reports paper in experimental colitis and a 2019 Experimental Eye Research paper on endothelial colony-forming cells in the ischaemic retina.
[3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]Reported mechanism
A nonerythropoietic peptide engineered from erythropoietin; the retrieved records report innate immune and tissue-protective endpoints rather than erythropoiesis.
[10, 4]Stated in the titles of the cited 2015 Molecular Medicine and 2016 Transplantation papers.
Targets named in the cited records: innate repair receptor, macrophage activation.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
ARA 290 appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- cibinetide
- ARA290
Where this page sits
Research records
Cited research records for ARA 290, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
- Larazotide — Tissue repair peptides
- BPC-157 — Tissue repair peptides
Class page: Tissue repair peptides. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for ARA 290?
ARA 290, generic name cibinetide, is described in a 2014 Molecular Pain paper as a peptide derived from the tertiary structure of erythropoietin and in a 2016 Transplantation paper as a nonhematopoietic erythropoietin analogue. A 2020 Toxicology in Vitro paper reports attenuation of doxorubicin-induced genotoxicity in its model, and a 2022 Brain, Behavior and Immunity paper reports early monocyte modulation in a model of Alzheimer-like pathology.
Which class is ARA 290 indexed under?
ARA 290 is indexed under Tissue repair peptides. This grouping covers peptides whose retrieved research literature is predominantly concerned with tissue repair endpoints in laboratory and animal models, rather than a single shared receptor.
What does the FDA application register show for ARA 290?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- PubChem Compound Summary for CID 91810664, Cibinetide. PubChem, National Library of Medicine (2026). pubchem:91810664
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:ara-290
- ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Molecular pain (2014). pmid:24529189
- A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets. Transplantation (2016). pmid:26683514
- An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress. Toxicology in vitro : an international journal published in association with BIBRA (2020). pmid:32335150
- Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression. Brain, behavior, and immunity (2022). pmid:34343617
- Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Molecular medicine (Cambridge, Mass.) (2012). pmid:23168581
- ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Molecular medicine (Cambridge, Mass.) (2013). pmid:24136731
- ARA 290 for treatment of small fiber neuropathy in sarcoidosis. Expert opinion on investigational drugs (2014). pmid:24555851
- ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Molecular medicine (Cambridge, Mass.) (2015). pmid:25387363
- Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Investigative ophthalmology & visual science (2017). pmid:28475703
- Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis. Scientific reports (2017). pmid:29026145
- The vasoreparative potential of endothelial colony-forming cells in the ischemic retina is enhanced by cibinetide, a non-hematopoietic erythropoietin mimetic. Experimental eye research (2019). pmid:30876881
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.